{
    "clinical_study": {
        "@rank": "82205", 
        "arm_group": [
            {
                "arm_group_label": "everolimus", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Everolimus administration with adjusted dose to target C trough (C0) level between 3-12 ng/mL"
            }, 
            {
                "arm_group_label": "everolimus with atorvastatin 20 mg", 
                "arm_group_type": "Experimental", 
                "description": "Co-administration of everolimus and atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.\nAtorvastatin 20 mg/day (fixed dose)"
            }
        ], 
        "brief_summary": {
            "textblock": "Hypothesis : In renal transplantation recipient who received immunosuppressive drug\n      \"certican\" and have hypercholesterolemia will get lipid lower drug-HMG Co-A reductase\n      inhibitors. Because atorvastatin and everolimus have metabolism via Cytochrome P450\n      subfamily 3A4 both, so investigator made the hypothesis that when patients received\n      everolimus with atorvastatin will change area under the time concentration curve of\n      everolimus."
        }, 
        "brief_title": "Pharmacokinetic of Everolimus and Atorvastatin Co-administration", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Difference of 12-hour AUC", 
        "detailed_description": {
            "textblock": "Population : Thai postrenal transplantation recipient who received everolimus and have\n      hypercholesterolemia in posttransplantation clinic at Faculty of Medicine, Chulalongkorn\n      University.\n\n      Study Design : Experimental study, Two-sample crossover study Sample size calculation :N =\n      18 Primary outcome : 12-hour area under the time concentration curve of everolimus Secondary\n      outcome : renal function (serum creatinine, creatinine clearance)\n\n      Method :\n\n        1. Patients will random to everolimus or everolimus with atorvastatin 20 mg arm for 1\n           month.\n\n        2. Take blood sample for everolimus concentration at time 0,0.5, 1, 1.5, 2, 2.5, 4, 6, 8,\n           12 hour\n\n        3. After first blood sample, patients will received everolimus only for 1 month (wash out\n           period)\n\n        4. Patients will switch to another arm eg.patient who had received everolimus will switch\n           to everolimus with atorvastatin 20 mg for 1 month\n\n        5. Take blood sample for everolimus concentration at time 0,0.5, 1, 1.5, 2, 2.5, 4, 6, 8,\n           12 hour\n\n        6. Everolimus level will analyse for 12-hour AUC of everolimus."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Post renal transplantation recipient who received immunosuppressive drug Everolimus\n             and has hypercholesterolemia\n\n          -  Co everolimus level within 3-12 ng/mL\n\n          -  Informed consent\n\n          -  Patient can follow research methodology\n\n        Exclusion Criteria:\n\n          -  Patient don't want to participate in the study\n\n          -  Post renal transplantation recipient who have normal lipid profile"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01780948", 
            "org_study_id": "A7478"
        }, 
        "intervention": [
            {
                "arm_group_label": "everolimus", 
                "description": "Add atorvastatin 20 mg and compare 12-hour AUC of everolimus between Arm everolimus and everolimus with atorvastatin 20 mg", 
                "intervention_name": "Atorvastatin 20 mg", 
                "intervention_type": "Drug", 
                "other_name": "Lipitor 20 mg"
            }, 
            {
                "arm_group_label": "everolimus with atorvastatin 20 mg", 
                "description": "Administration only everolimus, no atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.", 
                "intervention_name": "Everolimus", 
                "intervention_type": "Drug", 
                "other_name": "Everolimus alone"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus", 
                "Atorvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Drug Interaction", 
            "Pharmacokinetics", 
            "Everolimus", 
            "Atorvastatin"
        ], 
        "lastchanged_date": "February 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bangkok", 
                    "country": "Thailand", 
                    "zip": "10330"
                }, 
                "name": "King Chulalongkorn Memorial Hospital"
            }
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "2", 
        "official_title": "Drug Interaction and Pharmacokinetic Assessment of Everolimus When Coadministered With Atorvastatin in Renal Transplantation Recipient", 
        "other_outcome": {
            "description": "To correlate between 12-hour AUC and point of everolimus level", 
            "measure": "Correlation of 12-hour AUC and point of everolimus level", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "overall_official": {
            "affiliation": "Chulalongkorn University", 
            "last_name": "Anocha Wanitchanont, MD.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Thailand: Ethical Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "compare when taking only everolimus to coadministered with atorvastatin", 
            "measure": "12-hour area under the time concentration curve of everolimus", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "reference": {
            "PMID": "11831546", 
            "citation": "Kovarik JM, Hartmann S, Hubert M, Berthier S, Schneider W, Rosenkranz B, Rordorf C. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. J Clin Pharmacol. 2002 Feb;42(2):222-8."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01780948"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chulalongkorn University", 
            "investigator_full_name": "ANOCHA WANITCHANONT", 
            "investigator_title": "Department of Medicine, Faculty of Medicine, Chulalongkorn University", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Renal function : serum creatinine, 24 hour creatinine clearance 24 hour urine protein, Urinalysis Sample take at month 0,1,2,3", 
                "measure": "Renal function", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Total protein, Albumin, total bilirubin, direct bilirubin, AST, ALT, Alkaline phosphatase at month 0,1,2,3", 
                "measure": "Liver function test", 
                "safety_issue": "Yes", 
                "time_frame": "3 month"
            }, 
            {
                "description": "Total cholesterol, Triglyceride, HDL, LDL at month 0,1,2,3", 
                "measure": "Lipid profile", 
                "safety_issue": "Yes", 
                "time_frame": "3 month"
            }, 
            {
                "description": "Adverse drug reaction from atorvastatin by measured CPK at month 0,1,2,3", 
                "measure": "Rhabdomyolysis", 
                "safety_issue": "Yes", 
                "time_frame": "3 month"
            }
        ], 
        "source": "Chulalongkorn University", 
        "sponsors": {
            "collaborator": {
                "agency": "Ratchadapiseksompotch Research Fund", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Chulalongkorn University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}